循環器臨床サピア　5　患者アウトカムからみた不整脈の薬物治療

出版社： 中山書店
著者：
発行日： 2010-02-25
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784521731650
シリーズ： 循環器臨床サピア
電子書籍版： 2010-02-25 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

11,000 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

11,000 円(税込)

購入する

商品紹介

本書は，実地臨床において「治療すべき不整脈」「放置してよい不整脈」をどのようにに見分け，いかに薬を使うべきかについて，変遷をとげる不整脈治療に習熟する第一線の臨床医がわかりやすく解説した最新版のテキストである。

目次

  • 循環器臨床サピア　5　患者アウトカムからみた不整脈の薬物治療

    ―目次―

    1章　不整脈薬物療法の基礎
    2章　治療すべき不整脈・放置してよい不整脈
    3章　上室性不整脈の薬物療法
    4章　心室性不整脈の薬物療法
    5章　徐脈性不整脈の薬物療法
    6章　合併症に伴う不整脈治療
    7章　不整脈薬物療法と非薬物療法

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 不整脈薬物療法の基礎

P.9 掲載の参考文献
1) Wijffels MC, et al. Atrial fibrillation begets atrial fibrillation. Circulation 1995 ; 92 : 1954-1968.
PubMed
2) Kato T, et al. Progressive nature of paroxysmal atrial fibrillation : Observations from a 14-year follow-up study. Circ J 2004 ; 68 : 568-572.
PubMed
3) Healey JS, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers : A meta-analysis. J Am Coll Cardiol 2005 ; 45 : 1832-1839.
PubMed
4) Kato T, et al. What are arrhythmogenic substrates in diabetic rat atria? J Cardiovasc Electrophysiol 2006 ; 17 : 890-894.
 
5) Kato T, et al. AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. J Cardiovasc Electrophysiol 2008 ; 19 : 415-420.
 
6) GISSI-AF investigators. Valsartan for prevension of recurrent atrial fibrillation. N Engl J Med 2009 ; 360 : 1606-1617.
 
P.19 掲載の参考文献
1) Nerbonne JM, et al. Molecular physiology of cardiac repolarization. Physiol Rev 2005 ; 85 : 1205-1253.
PubMed
2) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 不整脈薬物治療に関するガイドライン (2009年改訂版 <JCS2009>). http://www.j-circ.or.jp/guideline/pdf/JCS2009_kodama_h.pdf
 
3) Jongsma H, et al. Gap junctions in cardiovascular disease. Circ Res 2000 ; 86 : 1193-1197.
PubMed
4) Ludwig A, et al. Two pacemaker channels from human heart with profoundly different activation kinetics. EMBO J 1999 ; 18 : 2323-2329.
PubMed
5) 井上博, 山下武志 (編). 不整脈クリニカルプラクティス-不整脈専門医をめざして. 東京 : 南江堂 ; 2009.
 
P.26 掲載の参考文献
1) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 不整脈薬物治療に関するガイドライン (2009年改訂版 <JCS 2009>). http://www.j-circ.or.jp/guideline/pdf/JCS2009_kodama_h.pdf
 
2) Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation : Current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace 2008 ; 10 : 647-665.
PubMed
3) 加藤貴雄. 不整脈薬物療法の新しい考え方Sicilian Gambitの臨床応用. J Nippon Med Sci 2002 ; 69 : 7-12.
 
4) 抗不整脈薬ガイドライン委員会 (編). 抗不整脈薬ガイドライン-CD-ROM版ガイドラインの解説とシシリアンガンビットの概念. 東京 : ライフメディコム ; 2000.
 
P.33 掲載の参考文献
1) Members of the Sicilian Gambit. New approaches to antiarrhythmic therapy, Part I : Emerging therapeutic applications of the cell biology of cardiac arrhythmias. Circulation 2001 ; 104 : 2865-2873.
PubMed
1) Boos CJ, et al. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006 ; 27 : 136-149.
PubMed
2) Inoue N, et al. Rapid electrical stimulation of contraction modulates gap junction protein in neonatal rat cultured cardiomyocytes : Involvement of mitogen-activated protein kinases and effects of angiotensin II-receptor antagonist. J Am Coll Cardiol 2004 ; 44 : 914-922.
PubMed
2) Lozano HF, et al. Treatment and prevention of atrial fibrillation with non-antiarrhythmic pharmacologic therapy. Heart Rhythm 2005 ; 2 : 1000-1007.
PubMed
3) Madrid AH, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation : A prospective and randomized study. Circulation 2002 ; 106 : 331-336.
PubMed
3) Ozaydin M, et al. N-acetylcysteine for the prevention of postoperative atrial fibrillation : A prospective, randomized, placebo-controlled pilot study. Eur Heart J 2008 ; 29 : 625-631.
PubMed
4) Anand K, et al. Meta-analysis : Inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 2006 ; 152 : 217-222.
PubMed
4) Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein : Rationale and design of the JUPITER trial. Circulation 2003 ; 108 : 2292-2297.
PubMed
5) Den Ruijter HM, et al. Pro- and antiarrhythmic properties of a diet rich in fish oil. Cardiovasc Res 2007 ; 73 : 316-325.
 
5) Chung MK, et al. C-reactive protein elevation in patients with atrial arrhythmias : Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001 ; 104 : 2886-2891.
PubMed
6) Calo L, et al. N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery : A randomized, controlled trial. J Am Coll Cardiol 2005 ; 45 : 1723-1728.
 
6) Fauchier L, et al. Antiarrhythmic effect of statin therapy and atrial fibrillation a metaanalysis of randomized controlled trials. J Am Coll Cardiol 2008 ; 51 : 828-835.
PubMed
7) Kato T, et al. AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. J Cardiovasc Electrophysiol 2008 ; 19 : 415-420.
 
8) Packer M, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group. N Engl J Med 1996 ; 334 : 1349-1355.
 
9) Lindholm LH, et al. Effect of losartan on sudden cardiac death in people with diabetes : Data from the LIFE study. Lancet 2003 ; 362 : 619-620.
PubMed
10) Brouwer IA, et al. Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. Eur Heart J 2009 ; 30 : 820-826.
PubMed
P.40 掲載の参考文献
1) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2006-2007年合同研究班報告). 心房細動治療 (薬物) ガイドライン (2008年改訂版 <JCS2008>). Circ J 2008 ; 72 (Suppl IV) : 1581-1638.
 
2) Yamashita T, et al. Thrombomodulin and tissue factor pathway inhibitor in endocardium of rapidly paced rat atria. Circulation 2003 ; 108 : 2450-2452.
PubMed
3) Goto S. Understanding the mechanism and prevention of arterial occlusive thrombus formation by anti-platelet agents. Curr Med Chem Cardiovasc Hematol Agents 2004 ; 2 : 149-156.
PubMed
4) 青崎正彦ほか (監修). Warfarin適正使用情報, 第3版. 東京 : エーザイ ; 2006.
 
5) Albers GW, et al ; SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation : A randomized trial. JAMA 2005 ; 293 : 690-698.
 
6) 後藤信哉. 冠動脈疾患と抗血小板薬. 木村一雄, 土師一夫 (編). 新・心臓病診療プラクティス 5 冠動脈疾患を診る II. 東京 : 文光堂 ; 2005. pp. 35
 
7) Connolly SJ, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 ; 361 : 1139-1151.
PubMed
P.47 掲載の参考文献
1) Yasuda M, et al. Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. Circ J 2006 ; 70 : 662-666.
PubMed
2) Sadanaga T, Ogawa S. Bepridil produces prominent bradycardia-dependent QT prolongation in patients with structural heart disease. J Electrocardiol 2007 ; 40 : 426-431.
 
3) Lehmann MH, et al. Sex difference in risk of torsade de pointes with d, l-sotalol. Circulation 1996 ; 94 : 2535-2541.
 
4) Echt DS, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo : The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991 ; 324 : 781-788.
 
5) Morita H, et al. Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome. J Am Coll Cardiol 2003 ; 42 : 1624-1631.
PubMed
P.52 掲載の参考文献
1) Lesar TS, et al. Factors related to errors in medication prescribing. JAMA 1997 ; 277 : 312-317.
PubMed
2) 日本老年医学会 (編). 高齢者の安全な薬物療法ガイドライン 2005. 東京 : メジカルビュー社 ; 2005.
 
3) Fick DM, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults : Results of a US consensus panel of experts. Arch Intern Med 2003 ; 163 : 2716-2724.
PubMed
4) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report : Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989 ; 321 : 406-412.
 
5) Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 ; 347 : 1825-1833.
 
6) 秋下雅弘ほか. 高齢者薬物療法の問題点-大学病院老年科における薬物有害作用の実態調査. 日老医誌 2004 ; 41 : 303-306.
 
P.59 掲載の参考文献
1) Ludmer PL, et al. Circadian variation of sudden cardiac death. J Am College Cardiol 1986 ; 7 (2) : 209A.
 
2) Lawn B, et al. Sleep and ventricular premature beats. Circulation 1973 ; 48 : 691-701.
 
3) Kasanuki H, et al. Idiopathic ventricular fibrillation induced with vagal activity in patient without obvious heart disease. Circulation 1997 ; 95 : 2277-2285.
PubMed
4) 赤城格ほか. 発作性心房細動発現直前の自律神経緊張変化とジソピラミドの有効性について. 循環器科 2006 ; 59 (2) : 191-197.
 

2章 治療すべき不整脈・放置してよい不整脈

P.68 掲載の参考文献
1) Smith RF. The Wolff-Parkinson-White syndrome as an aviation risk. Circulation 1964 ; 29 : 672-679.
PubMed
2) 加藤勲. 生徒の不整脈の特徴. WPW 症候群と心室性期外収縮. 若年者心疾患対策協議会誌 2005 ; 33 : 57-64.
 
3) 奥村謙. 上室性不整脈 (2) 発作性上室頻拍. 井上博 (編). エキスパートをめざす循環器診療 不整脈. 東京 : 南江堂 ; 2006. pp165-177.
 
4) Feinberg WM, et al. Prevalence, age, distribution, and gender of patients with atrial fibrillation. Arch Intern Med 1995 ; 155 : 469-473.
PubMed
5) Wolf PA, et al. Secular trends in the prevalence of atrial fibrillation : The Framingham study. Am Heart J 1996 ; 131 : 790-795.
PubMed
6) 橋場邦武. 老年者の不整脈. 日老医誌 1989 ; 26 : 101-110.
 
7) Inoue H, et al. Prevalence of atrial fibrillation in the general population of Japan : An analysis based on periodic health examination. Int J Cardiol 2009 ; 137 : 102-107.
PubMed
8) Watanabe H, et al. Metabolic syndrome and risk of development of atrial fibrillation : The Niigata preventive medicine study. Circulation 2008 ; 117 : 1255-1260.
PubMed
9) 北村明彦ほか. 秋田農村における心房細動に関する疫学的検討. 日本公衛誌 1991 ; 38 : 95-105.
 
10) 奥村謙ほか. 心原性脳塞栓のクリティカルケア-心房細動の管理の重要性. クリニシアン 2007 ; 54 : 343-353.
 
11) The Atrial Fibrillation Follow-up Investigation of Rhythm Management (心房細動 FIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 ; 347 : 1825-1833.
 
12) Van Gelder IC, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002 ; 347 : 1834-1840.
PubMed
13) Gage BF, et al. Validation of clinical classification schemes for predicting stroke : Results from the national registry of atrial fibrillation. JAMA 2001 ; 285 : 2864-2870.
 
14) Hylek EM, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007 ; 115 : 2689-2696.
PubMed
15) Yasaka M, et al. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001 ; 40 : 1183-1188.
PubMed
16) Wilde AA, et al. Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J 2002 ; 23 : 1648-1654.
PubMed
17) Atarashi H, et al. Three-year follow-up of patients with right bundle branch block and ST segment elevation in the right precordial leads : Japanese registry of Brugada syndrome. J Am Coll Cardiol 2001 ; 37 : 1919-1920.
 
18) Miyasaka Y, et al. Prevalence and mortality of the Brugada-type electrocardiogram in one city in Japan. J Am Coll Cardiol 2001 ; 38 : 771-774.
PubMed
19) Hermida JS, et al. Prevalence of the Brugada syndrome in an apparently healthy population. Am J Cardiol 2000 ; 86 : 91-94.
 
20) Matsuo K, et al. The prevalence, incidence and prognostic value of the Brugada-type electrocardiogram : A population-based study of four decades. J Am Coll Cardiol 2001 ; 38 : 765-770.
PubMed
21) Yamakawa Y, et al. Prevalence of right bundle-branch block and right precordial ST-segment elevation (Brugada-type electrocardiogram ) in Japanese children. Virc J 2004 ; 68 : 275-279.
 
22) Brugada J, et al. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation 2002 ; 105 : 73-78.
PubMed
23) Eckardt L, et al. Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation 2005 ; 111 : 257-263.
PubMed
24) Kamakura S, et al. Long-term prognosis of probands with Brugada-pattern ST elevation in V1-V3 leads. Circ Arrhythm Electrophysiol, 2009 ; 2 : 495-503.
PubMed
P.74 掲載の参考文献
1) Levy S, et al. Characterization of different subsets of atrial fibrillation in general practice in France : The ALFA study. Circulation 1999 ; 99 : 3028-3035.
PubMed
2) 下村克朗. 不整脈と不定愁訴. Pharma Medica 1992 ; 10 : 9-10.
 
3) Page RL, et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994 ; 89 : 224-227.
PubMed
4) 碓井雅博ほか. 心室期外収縮の治療効果判定に自覚症状の改善は有用な指標となるか? 心電図 1998 ; 18 : 824-829.
Medical*Online
5) Yarlagadda RK, et al. Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract. Circulation 2005 ; 112 : 1092-1097.
PubMed
6) Clark DM, et al. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 1997 ; 30 : 1039-1045.
PubMed
7) Bayes de Luna A, et al. Ambulatory sudden cardiac death : Mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989 ; 117 : 151-159.
PubMed
8) Katritsis DG, et al. Nonsustained ventricular tachycardia : Where do we stand? Eur Heart J 2004 ; 25 : 1093-1099.
PubMed

3章 上室性不整脈の薬物療法

P.81 掲載の参考文献
1) Katoh T, et al. Multicenter survey on the validity of the CD-ROM guideline for antiarrhythmic drug therapy produced by the Japanese Circulation Society and the Japanese Society on Electrocardiology : Preliminary report of the survey of the Japanese guideline for arrhythmia management by individual therapy (J-GAMBIT). Circ J 2005 ; 69 : 1357-1360.
PubMed
2) Haissaguerre M, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998 ; 339 : 659-666.
PubMed
3) 児玉逸雄. Na チャネル遮断作用-modulated receptor仮説. 小川聡ほか (編). 抗不整脈薬のすべて. 東京 : 先端医学社 ; 1997. pp. 71-82.
 
4) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 不整脈薬物治療に関するガイドライン (2009年改訂版 <JCS2009>). http://www.j-circ.or.jp/guideline/pdf/JCS2009_kodama_h.pdf
 
P.86 掲載の参考文献
1) Wood KA, et al. Frequency of disabling symptoms in supraventricular tachycardia. Am J Cardiol 1997 ; 79 : 145-149.
PubMed
2) Fitzsimmons PJ, et al. The natural history of Wolff-Parkinson-White syndrome in 228 military aviators : A long-term follow-up of 22 years. Am Heart J 2001 ; 142 : 530-536.
PubMed
3) Timmermans C, et al. Aborted sudden death in the Wolff-Parkinson-White syndrome. Am J Cardiol 1995 ; 76 : 492-494.
PubMed
4) Klein GJ, Gulamhusein SS. Intermittent preexcitation in the Wolff-Parkinson-White syndrome. Am J Cardiol 1983 ; 52 : 292-296.
PubMed
5) Easley AR Jr, et al. Intermittent preexcitation : Marked enhancement of anterograde conduction in the atrioventricular accessory pathway with isoproterenol. Pacing Clin Electrophysiol 1988 ; 11 : 349-354.
PubMed
P.91 掲載の参考文献
1) Morita N, et al. Effect of nifekalant for acute conversion of atrial flutter : The possible termination mechanism of typical atrial flutter. Pacing Clin Electrophysiol 2007 ; 30 : 1242-1253.
PubMed
2) Falk RH, et al. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol 1997 ; 29 : 385-390.
PubMed
3) Crijns HJ, et al. Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug. Eur Heart J 1994 ; 15 : 1403-1408.
 
4) Tai CT, et al. Electropharmacologic effects of class I and class III antiarrhythmia drugs on typical atrial flutter : Insights into the mechanism of termination. Circulation 1998 ; 97 : 1935-1945.
 
5) Ghali WA, et al. Atrial flutter and the risk of thromboembolism : A systematic review and meta-analysis. Am J Med 2005 ; 118 : 101-107.
PubMed
P.98 掲載の参考文献
1) Wyse DG, et al ; The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 ; 347 : 1825-1833.
 
2) Isaabelle C, et al. A comparison of rate control and rhythm control in patient with recurrent persistent atrial fibrillation. N Engl J Med 2002 ; 347 : 1834-1840.
 
3) AFFIRM investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM ) study. Circulation 2004 ; 109 : 1509-1513.
PubMed
4) Ogawa S, et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation. Circ J 2009 ; 73 : 242-248.
PubMed
5) ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary : A Report of the American College Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006 ; 144 : 700-752.
 
6) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2006-2007年度合同研究班報告). 心房細動治療 (薬物) ガイドライン (2008年改訂版 <JCS 2008>). Circ J 2008 ; 72 (Suppl IV) : 1581-1638.
 
7) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 不整脈薬物治療に関するガイドライン (2009年改訂版 <JCS2009>). http://www.j-circ.or.jp/guideline/pdf/JCS2009_kodama_h.pdf
 
P.105 掲載の参考文献
1) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2006-2007年度合同研究班). 心房細動治療 (薬物) ガイドライン (2008年改訂版 <JCS 2008>). Circ J 2008 ; 72 (Suppl IV) : 1581-1638.
 
2) Fuster V, et al. Guidelines for the management of patients with atrial fibrillation. Executive summary. Eur Heart J 2006 ; 27 : 1979-2030.
PubMed
3) Gage BF, et al. Validation of clinical classification schemes for predicting stroke : Results from the National Registry of Atrial Fibrillation. JAMA 2001 ; 285 : 2864-2870.
 
4) Inoue H, et al. Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation. Circ J 2006 ; 70 : 651-656.
PubMed
5) Atrial Fibrillation Investigators : Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation : Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994 ; 154 : 1449-1457.
 
6) Yamaguchi T for Japanese NVAF-Embolism Secondary Prevention Cooperative Study Group. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation. A multicenter prospective randomized trial. Stroke 2000 ; 31 : 817-821.
 
7) Yasaka M, et al. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001 ; 40 : 1183-1188.
PubMed
8) Hohnloser SH, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy : An ACTIVE W Substudy. J Am Coll Cardiol 2007 ; 50 : 2156-2161.
PubMed
9) Sato H, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation : Japan atrial fibrillation stroke trial. Stroke 2006 ; 37 : 447-451.
PubMed
10) The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W) : A randomised controlled trial. Lancet 2006 ; 367 : 1903-1912.
 
11) Toyoda K, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease : A prospective, multicenter, observational study. Stroke 2008 ; 39 : 1740-1745.
PubMed
12) Yasaka M, et al. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res 2002 ; 108 : 25-30.
PubMed
P.109 掲載の参考文献
1) Jackman WM, et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome ) by radifrequency current. N Engl J Med 1991 ; 324 : 1605-1611.
 
1) Klein GJ, Gulamhusein SS. Intermittent preexcitation in the Wolff-Parkinson-White syndrome. Am J Cardiol 1983 ; 52 : 292-296.
PubMed
1) Munger TM, et al. A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953-1989. Circulation 1993 ; 87 : 866-873.
PubMed
1) Klein GJ, et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med 1979 ; 301 : 1080-1085.
PubMed
1) Pappone C, et al. Usefulness of invasive electrophysiologic testing to stratify the risk of arrhythmic events in asymptomatic patients with Wolff-Parkinson-White pattern : Results from a large prospective long-term follow-up study. J Am Coll Cardiol 2003 ; 41 (2) : 239-244.
PubMed
1) Eshchar Y, et al. Comparison of exercise and ajmaline tests with electrophysiologic study in the Wolff-Parkinson-White syndrome. Am J Cardiol 1986 ; 57 : 782-786.
PubMed
2) Pappone C, et al. Radiofrequency ablation in children with asymptomatic Wolff-Parkinson-White syndrome. N Engl J Med 2004 ; 351 : 1197-1205.
PubMed
2) Fananapazir L, et al. Procainamide infusion test : Inability to identify patients with Wolff-Parkinson-White syndrome who are potentially at risk of sudden death. Circulation 1988 ; 77 : 1291-1296.
PubMed
2) Sharma AD, et al. Sensitivity and specificity of invasive and noninvasive testing for risk of sudden death in Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1987 ; 10 : 373-381.
PubMed
2) Fitzsimmons P, et al. The natural history of Wolff-Parkinson-White syndrome in 228 military aviators : A long-term follow-up of 22 years. Am Heart J 2001 ; 142 : 530-536.
PubMed
2) Montoya PT, et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. Eur Heart J 1991 ; 12 : 144-150.
PubMed
2) Santinelli V, et al. The natural history of asymptomatic ventricular pre-excitation. J Am Coll Cardiol 2009 ; 53 (3) : 275-280.
PubMed
3) Auricchio A, et al. Lack of prognostic value of syncope in patients with Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1991 ; 17 : 152-158.
PubMed
3) Leitch JM, et al. Prognostic value of electrophysiology testing in asymptomatic patients with Wolff-Parkinson-White pattern. Circulation 1990 ; 82 : 1718-1723.
 
3) Timmermans C, et al. Aborted sudden death in the Wolff-Parkinson-White syndrome. Am J Cardiol 1995 ; 76 : 492-494.
PubMed
4) Klein GJ, et al. Asymptomatic Wolff-Parkinson-White : Should we intervene? Circulation 1989 ; 80 : 1902-1905.
PubMed
4) Waldo AL, et al. Appropriate electrophysiologic study and treatment of patients with the Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1988 ; 11 : 1124-1129.
PubMed
5) Wellens HJ. Should catheter ablation be performed in asymptomatic patients with Wolff-Parkinson-White syndrome? When to perform catheter ablation in asymptomatic patients with a Wolff-Parkinson-White electrocardiogram. Circulation 2005 ; 112 : 2201-2207.
 
6) Pappone C, et al. A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome. N Engl J Med 2003 ; 349 : 1803-1811.
PubMed

4章 心室性不整脈の薬物療法

P.117 掲載の参考文献
1) Task force of the working group on arrhythmia of the European Society of Cardiology. The Sicilian Gambit : A new approach to the classification of arrhythmic drugs based on their action on arrhythmogenic mechanisms. Circulation 1991 ; 84 : 1831-1851.
 
2) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 不整脈薬物治療に関するガイドライン (2009年改訂版 <JCS 2009>). http://www.j-circ.or.jp/guideline/pdf/JCS2009_kodama_h.pdf
 
3) Echt DS, et al. Mortality and morbidity in patients receiving encanide, flecainide, or placebo : The Cardiac Arrhythmia Suppression Trial. New Engl J Med 1991 ; 324 : 781-788.
 
4) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2006-2007年度合同研究班報告), 急性心筋梗塞 (ST 上昇型) の診療に関するガイドライン. Cir J 2008 ; 72 (Suppl IV) : 1375.
 
5) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2005年度合同研究班報告), 不整脈の非薬物治療ガイドライン (2006年改訂版 <JCS 2006>). http://www.j-circ.or.jp/guideline/pdf/JCS2006_kasanuki_h.pdf
 
P.126 掲載の参考文献
1) Buxton AE, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1996 ; 341 : 1882-1890.
 
2) Echt DS, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo : The cardiac arrhythmia suppression trial. N Engl J Med 1991 ; 324 : 781-788.
 
3) Buxton AE, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Investigators. N Engl J Med 2000 ; 342 : 1937-1945.
 
4) Moss AJ, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996 ; 335 : 1933-1940.
 
5) Pires LA, et al. Multicenter Unsustained Tachycardia Trial Investigators. Differences in inducibility and prognosis of in-hospital versus out-of-hospital identified nonsustained ventricular tachycardia in patients with coronary artery disease : Clinical and trial design implications. J Am Coll Cardiol 2001 ; 38 : 1156-1162.
PubMed
6) Moss AJ, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 ; 346 : 877-883.
PubMed
7) Doval HC, et al. Nonsustained ventricular tachycardia in severe heart failure : Independent marker of increased mortality due to sudden death. GESICA-GEMA Investigators. Circulation 1996 ; 94 : 3198-3203.
PubMed
8) Singh SN, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995 : 333 ; 77-82.
PubMed
9) Bardy GH, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT ) Investigators. Amiodarone or implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005 ; 352 : 225-237.
 
10) Kadish A, et al. Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE ) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004 ; 350 : 2151-2158.
PubMed
11) Strickberger SA, et al. AMIOVIRT Investigators. Amiodarone versus implantable cardioverter-defibrillator : Randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol 2003 ; 41 : 1707-1712.
PubMed
12) Maron BJ, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000 ; 342 : 365-373.
PubMed
P.134 掲載の参考文献
1) AHA. 2005 AHA Guideline for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2005 ; 112 (Suppl I-24 ) : IV1-203.
 
2) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 不整脈薬物治療に関するガイドライン (2009年改訂版 <JCS 2009>). http://www.j-circ.or.jp/guideline/pdf/JCS2009_kodama_h.pdf
 
3) Gorgels AP, et al. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol 1996 ; 78 : 43-46.
PubMed
4) Ezekowvitz JA, et al. Implantable cardioverter defibrillators in primary and secondary prevention : A systematic review of randomized, controlled trials. Ann Intern Med 2003 ; 138 : 445-452.
 
5) Bardy GH, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005 ; 352 : 225-237.
 
P.142 掲載の参考文献
1) Snellen HA. History of Cardiology. Rotterdam : Donker Academic Publications ; 1984. p. 141.
 
2) Bayes de Luna A, et al. Ambulatory sudden death : Mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989 ; 117 : 151-159.
PubMed
3) Epstein AE. Ventricular fibrillation. In : Zipes DP, et al (editors ). Cardiac Electrophysiology : From Cell to Bedside, 4th edition. Philadelphia : WB Saunders ; 2005. pp. 705-709.
 
4) Noda T, et al. Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initiated by premature extrasystoles originating from the right ventricular outflow tract. J Am Coll Cardiol 2005 ; 46 : 1288-1294.
PubMed
P.147 掲載の参考文献
1) Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death : A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Col Cardiol 2006 ; 48 : e247-e346.
 
2) Miyazaki T, et al. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Col Cardiol 1996 ; 27 : 1061-1070.
 
3) Yan GX. Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 1999 ; 100 : 1660-1666.
PubMed
4) Kasanuki H, et al. Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. Circulation 1997 ; 95 : 2277-2285.
PubMed
5) Ohgo T, et al. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm 2007 ; 4 : 695-700.
PubMed
6) Antzelevitch C. The Brugada syndrome. J Cardiovasc Electrophysiol 1998 ; 9 : 513-516.
PubMed
7) Belhassen B, et al. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 2004 ; 110 : 1731-1737.
PubMed
8) Alings M, et al. Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. Pacing Clin Electrophysiol 2001 ; 24 : 1420-1422.
PubMed
9) Mizusawa Y, et al. Effects of low-dose quinidine on ventricular tachyarrhythmias in patients with Brugada syndrome : Low-dose quinidine therapy as an adjunctive treatment. J Cardiovasc Pharmacol 2006 ; 47 : 359-364.
PubMed
10) Tsuchiya T, et al. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2002 ; 13 : 698-701.
 
11) Sugao M, et al. Repolarization dynamics in patients with idiopathic ventricular fibrillation : Pharmacological therapy with bepridil and disopyramide. J Cardiovasc Pharmacol 2005 ; 45 : 545-549.
PubMed
P.154 掲載の参考文献
1) Shimizu W. The long QT syndrome : Therapeutic implications of a genetic diagnosis. Cardiovasc Res 2005 ; 67 : 347-356.
 
2) Shimizu W. Clinical impact of genetic studies in lethal inherited cardiac arrhythmias. Circ J 2008 ; 72 : 1926-1936.
PubMed
3) Schwartz PJ, et al. Genotype-phenotype correlation in the long-QT syndrome : Gene-specific triggers for life-threatening arrhythmias. Circulation 2001 ; 103 : 89-95.
 
4) Moss AJ, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation 2007 ; 115 : 2481-2489.
PubMed
5) Vincent GM, et al. High efficacy of β-blockers in long-QT syndrome type 1 : Contribution of noncompliance and QT-prolonging drugs to the occurrence of β-blocker treatment "failures". Circulation 2009 ; 119 : 215-221.
 
6) Shimizu W, et al. Genotype-phenotype aspects of type-2 long-QT syndrome. J Am Coll Cardiol 2009 ; 54 : 2052-2062.
PubMed
P.160 掲載の参考文献
1) Marcus FI, et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation : Results from the North American Multidisciplinary Study. Heart Rhythm 2009 ; 6 : 984-992.
PubMed
1) Sen-Chowdhry, et al. Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 2007 ; 50 : 1813-1821.
PubMed
2) Tabib A, et al. Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia. Circulation 2003 ; 108 : 3000-3005.
PubMed
3) McKenna WJ, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J 1994 ; 71 : 215-218.
 
4) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2003-2004年度合同研究班報告). 心臓突然死の予知と予防法のガイドライン (JCS 2005). Circ J 2005 ; 69 (Suppl IV ) : 1209-1252.
 
5) Corrado D, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2003 ; 108 : 3084-3091.
PubMed
P.168 掲載の参考文献
1) 津田冨康ほか. サルコイドーシスの診断基準と診断の手引き-2006 要約. 日サ会誌 2006 ; 26 : 77-82.
 
2) Valantine H, et al. Sarcoidosis : A pattern of clinical and morphological presentation. Heart 1987 ; 57 : 256-263.
PubMed
3) Kawamura Y, et al. A case of cardiac sarcoidosis : Significance of ventricular tachycardia originating from the septum. Jpn Circ J 1998 ; 62 : 458-461.
PubMed
4) Burstow DJ, et al. Two-dimensional echocardiographic findings in systemic sarcoidosis. Am J Cardiol 1989 ; 63 : 478-482.
PubMed
5) Grief M, et al. Cardiac sarcoidosis concealed by arrhythmogenic right ventricular dysplasia/cardiomyopathy. Nat Clin Pract Cardiovasc Med 2008 ; 5 : 231-236.
 
6) Casset-Senon D, et al. Recurrent ventricular tachycardia in cardiac sarcoidosis : Usefulness of fluorodeoxyglucose positron emission tomography for adequate management of corticoid therapy after placement of an implantable cardioverter defibrillator. J Nucl Cardiol 2008 ; 15 : 282-285.
PubMed
7) Jefic D, et al. Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis : Report from a multicenter registry. Heart Rhythm 2009 ; 6 : 189-195.
PubMed
P.172 掲載の参考文献
1) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2006年度合) 同研究班報告). 肥大型心筋症の診療に関するガイドライン (2007年改訂版).
 
2) Sumimoto T, et al. Effect of disopyramide on left ventricular diastolic function in patients with hypertrophic cardiomyopathy : Comparison with diltiazem. Cardiovasc Drugs Ther 1992 ; 6 : 425-428.
PubMed
3) Hamada M, et al. Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy. Jpn Circ J 2001 ; 65 : 531-538.
PubMed
4) Maron BJ, et al. Clinical course of hypertrophic cardiomyopathy in regional United States cohort. JAMA 1999 ; 281 : 650.
PubMed
5) Maron BJ, et al. Epidemiology of hypertrophic cardiomyopathy-related death : Revisited in a large non-referral-based patient population. Circulation 2000 ; 102 : 858.
 
P.181 掲載の参考文献
1) Kowey PR. An overview of antiarrhythmic drug management of electrical storm. Can J Cardiol 1996 ; 12 (Suppl B) : 3B-8B.
 
2) Credner SC, et al. Electrical storm in patients with transvenous implantable cardioverter-defibrillators : Incidence, management and prognostic implications. J Am Coll Cardiol 1998 ; 32 : 1909-1915.
PubMed
3) Verma A, et al. Prevalence, predictors, and mortality significance of the causative arrhythmia in patients with electrical storm. J Cardiovasc Electrophysiol 2004 ; 15 : 1265-1270.
 
4) Villacastin J, et al. Incidence and clinical significance of multiple consecutive, appropriate, high-energy discharges in patients with implanted cardioverter-defibrillators. Circulation 1996 ; 93 : 753-762.
PubMed
5) Zipes DP, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricu lar Arrhythmias and the Prevention of Sudden Cardiac Death : A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) : Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006 ; 114 : e385-484.
 
6) Nademanee K, et al. Treating electrical storm : Sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation 2000 ; 102 : 742-747.
PubMed

5章 徐脈性不整脈の薬物療法

P.190 掲載の参考文献
1) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2005年度合同研究班報告). 不整脈の非薬物治療ガイドライン (2006年改訂版 <JCS 2006>). http://www.j-circ.or.jp/guideline/pdf/JCS2006_kasanuki_h.pdf
 
2) Atarashi H, et al. Chronic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias. J Cardiovasc Pharmacol 1998 ; 31 : 534-539.
 
3) Saito D, et al. Effects of oral theophylline on sick sinus syndrome. J Am Coll Cardiol 1993 ; 21 : 1199-1204.
PubMed
4) 中里祐二. 症例から学ぶ不整脈治療におけるシロスタゾールの有用性. 臨床と研究 2007 ; 84 (9) : 108-112.
 
5) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 不整脈薬物治療に関するガイドライン (2009年改訂版 <JCS2009>). http://www.j-circ.or.jp/guideline/pdf/JCS2009_kodama_h.pdf
 
P.195 掲載の参考文献
1) Kikushima S, et al. Triggering mechanism for neurally mediated syncope induced by headup tilt test : Role of catecholamines and response to propranolol. J Am Coll Cardiol 1999 ; 33 : 350-357.
PubMed
2) Grubb BP, et al. Cerebral vasoconstriction during head-upright tilt-induced vasovagal syncope : A paradoxic and unexpected response. Circulation 1991 ; 84 : 1157-1164.
PubMed
3) Brignole M, et al. Guidelines on management (diagnosis and treatment ) of syncope : Update 2004. Europace 2004 ; 6 : 467-537.
PubMed
4) Madrid AH, et al. Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population : A prospective, double-blind, randomized and placebo-controlled study. J Am Coll Cardiol 2001 ; 37 : 554-559.
 
5) Sheldon R, et al. Prevention of Syncope Trial (POST ) : A randomized, placebo-controlled study of metoprolol in the prevention of vasovagal syncope. Circulation 2006 ; 113 : 1164-1170.
 
6) Minoura Y, et al. Hemodynamics changes after tilting and the efficacy of preventive drugs. Pacing Clin Electrophysiol 2008 ; 31 : 1130-1139.
PubMed

6章 合併症に伴う不整脈治療

P.204 掲載の参考文献
1) Benjamin EJ, et al. Independent risk factors for atrial fibrillation in a population-based cohort : The Framingham Heart Study. JAMA 1994 ; 271 : 840-844.
 
2) Pedersen OD, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1997 ; 100 : 376-380.
 
3) Maggioni AP, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure : Results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005 ; 149 : 548-557.
PubMed
4) Ducharme A, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candeartan in Heart failure : Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006 ; 152 : 86-92.
PubMed
5) Roy D, et al ; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008 ; 358 : 2667-2677.
PubMed
P.211 掲載の参考文献
1) Lopez-Sendon J, et al. Expert consensus document on β-adrenergic receptor blockers The Task Force on Beta-Blockers of the European Society of Cardiology. Eur Heart J 2004 ; 25 : 1341-1362.
 
2) Echt DS, et al ; CAST investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo : The cardiac arrhythmia suppression trial. N Engl J Med 1991 ; 324 : 781-788.
 
3) Domanski MJ, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction : A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999 ; 33 : 598-604.
PubMed
P.219 掲載の参考文献
1) Antman EM, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction : Executive summary : a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines on the Management of Patients With Acute Myocardial Infarction). Circulation 2004 ; 110 : 588-636.
PubMed
1) Callans D. Ventricular tachycardia in patients with coronary artery disease. In : Zipes DP, et al (editors). Cardiac Electrophysiology : From Cell to Bedside. Philadelphia : Saunders-Elsevier ; 2009, pp. 669-674.
 
2) Betts T, Kadish A. Arrhythmias in coronary artery disease. In : Saksena S, et al (editors). Electrophysiological Disorders of the Heart. Philadelphia : Elsevier-Churchill Livingston ; 2005, pp. 587-600.
 
2) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report : Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989 ; 321 : 406-412.
 
3) Moss AJ, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996 ; 335 : 1933-1940.
PubMed
4) Moss AJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 ; 346 : 877-883.
PubMed
P.225 掲載の参考文献
1) Go AS, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004 ; 351 : 1296-1305.
PubMed
2) Klausen K, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004 ; 110 : 32-35.
PubMed
3) Iguchi Y, et al. Relation of atrial fibrillation to glomerular filtration rate. Am J Cardiol 2008 ; 102 : 1056-1059.
PubMed
4) Matsuguma K, et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 2006 ; 17 : 2176-2183.
PubMed
P.235 掲載の参考文献
1) Kron J, Conti JB. Arrhythmias in the pregnant patient : Current concepts in evaluation and management. J Interv Card Electrophysiol 2007 ; 19 : 95-107.
 
1) Perloff JK, Koos B. Pregnancy and congenital heart disease : The mother and the fetus. In : Perloff JK, et al (editors). Congenital Heart Disease in Adults, 2nd edition. Philadelphia : WB Saunders ; 1998. pp. 144-164.
 
2) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2003-2004年度合同研究班報告). 心疾患患者の妊娠・出産の適応, 管理に関するガイドライン (JCS 2005). Circ J 2005 ; 69 (Suppl IV ) : 1267-1328.
 
2) Robson SC, et al. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol 1989 ; 256 : H1060-1065.
PubMed
3) Cox JL, Gardner MJ. Treatment of cardiac arrhythmias during pregnancy. Prog Cardiovasc Dis 1993 ; 36 (2) : 137-178.
PubMed
4) Tawam M, et al. Effect of pregnancy on paroxysmal supraventricular tachycardia. Am J Cardiol 1993 ; 72 (11) : 838-840.
PubMed
5) Chow T, et al. Antiarrhythmic drug therapy in pregnancy and lactation. Am J Cardiol 1998 ; 82 (4A) : 58I-62I.
PubMed
6) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 不整脈薬物治療に関するガイドライン (2009年改訂版 <JCS 2009>). http://www.j-circ.or.jp/guideline/pdf/JCS2009_kodama_h.pdf
 
7) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2006-2007年度合同研究班報告). 心房細動治療 (薬物) ガイドライン (2008年改訂版 <JCS 2008>). Circ J 2008 ; 72 (Suppl IV ) : 1581-1638.
 

7章 不整脈薬物療法と非薬物療法

P.244 掲載の参考文献
1) 山下武志. 心筋細胞の電気生理学-イオンチャネルから, 心電図, 不整脈へ. 東京 : メディカル・サイエンス・インターナショナル ; 2002.
 
2) 山下武志. 心が動けば医療も動く!? 医師と患者の治療選択. 東京 : メディカル・サイエンス・インターナショナル ; 2009.
 

書評

最近チェックした商品履歴

Loading...